LINTONPHARM
27.5.2022 15:02:13 CEST | Business Wire | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number：
e16102
Abstract Title：
Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1] . Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2] . Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com
Reference
1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Launches a Consultation on a Proposal to Reclassify Indonesia from Emerging Market to Standalone Market Status15.10.2026 23:47:00 CEST | Press release
MSCI to consult on proposal to reclassify the MSCI Indonesia Indexes to Standalone Market status Existing freeze on Indonesian securities in MSCI Indexes to remain in place until further notice MSCI announced the launch of a consultation on a proposal to reclassify the MSCI Indonesia Indexes from Emerging Market to Standalone Market status. MSCI will announce its final decision by the end of June 2027 and may provide an interim update on market participant feedback during the consultation period. As part of the June 2026 Market Classification Review, MSCI reported that market participants had raised significant concerns regarding the investability of the Indonesian equity market, including persistent opacity in shareholding structures and suspected coordinated trading behavior. While the Indonesian authorities have announced reforms, including enhanced disclosure of shareholders with ownership above 1%, more granular investor classification disclosure, High Shareholding Concentration (
Nekome: Nazi Hunter Unmasks Hitler’s Hyenas in New Trailer Ahead of Steam Next Fest Demo15.10.2026 21:38:00 CEST | Press release
Free demo offers players the first chance to pick up the knife in ProbablyMonsters’ narrative-driven action game beginning on October 19 ProbablyMonsters, an independent video game company creating original AA games with AAA sensibilities, today unveiled a new trailer for Nekome: Nazi Hunterat the Galaxies Autumn Showcase, pulling back the curtain on the game’s villains, Hitler’s Hyenas. Alongside the new trailer, ProbablyMonsters announced that Nekome: Nazi Hunter will participate in October’s Steam Next Fest, giving players their first opportunity to experience this violent odyssey of revenge with a free PC demo available on Steam from October 19 through 26. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014661905/en/ “Nekome is Vano’s story: an exploration of a young Romani man who has had everything taken away from him, and who decides to pick up a knife and exact revenge on his family’s murderers,” said Jeronimo Barr
The Estée Lauder Companies Announces BEAUTY&YOU India 2026 Winners and Marks Five Years of Advancing Indian Beauty Entrepreneurship15.10.2026 17:58:00 CEST | Press release
In partnership with Startup India and Nykaa, the program recognizes five winners across in-market beauty brands, early-stage concepts, fragrance innovation, creative design, and women’s entrepreneurship. The Estée Lauder Companies, in partnership with Nykaa and Startup India, an initiative of the Department for Promotion of Industry and Internal Trade (DPIIT) within India’s Ministry of Commerce and Industry, announced the winners of BEAUTY&YOU India 2026, the country’s leading beauty entrepreneurship program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015612324/en/ (L to R) BEAUTY&YOU India 2026 Winners Ajaykumar Mehta, Shriya Rambhia, and Dheer Rambhia, Directors, Goyam Green Tech (BREAKTHROUGH), Nirja Bhatt, Founder & CEO, Laani (GROW), Khatija Shabana, CEO, and Syed Mohammad Fouzan, Director, Boldpurity (IMAGINE), Rinzing Choden Bhutia, Founder, Agapi Sikkim (Visionary Women’s Award), and Pankti Sheth, Founder & Cr
Body of Waves, a New Artwork Only at teamLab Planets TOKYO, Unveiled15.10.2026 17:00:00 CEST | Press release
The visitor experiences offered by “Existence in the Flow Creates Vortices” and “Waterfall of Ephemeral Crystals” have also been further expanded. teamLab Planets TOKYO (hereinafter referred to as “teamLab Planets”) has unveiled Body of Waves, a new artwork in which visitors enter a soft sculpture with their entire bodies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014474897/en/ teamLab, Body of Waves, 2026, from the series Soft Black Hole - Your Body Becomes a Space that Influences Another Body, 2016-© teamLab *Shot in real space. No AI or CGI. In addition, Existence in the Flow Creates Vortices—where vortices are created behind people as they climb against the flow—and Waterfall of Ephemeral Crystals—where shining particles cascade down to create a waterfall of light particles—have also evolved, further expanding the experience at teamLab Planets. New Artwork Body of Waves As you walk, your feet sink. This force is
BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Restoration15.10.2026 17:00:00 CEST | Press release
Expanded vision reflects focus beyond wound care to advancing innovation across the full tissue restoration journey BioLab Holdings announced today a new, larger mission with the launch of EmeraNova™, a new corporate identity that reflects a broader ambition to advance tissue restoration across specialties, healing phases, and care settings. The launch marks the company’s efforts to build a global platform focused on identifying promising technologies and accelerating their path into clinical practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015721831/en/ EmeraNova seeks partners around the world to bring promising technologies to market quickly and equip clinicians with advanced, effective solutions. EmeraNova represents a vision to pursue emerging (Emer) and new (Nova) technologies by building an expanding toolbox of tissue restoration solutions, world-class support, and ways to bring together expert voices and c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom